Search Results - "KOROPATNICK, James"

CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts by Alotaibi, Faizah M, Min, Wei-Ping, Koropatnick, James

“…CD5 is a member of the scavenger receptor cysteine-rich superfamily that is expressed on T cells and a subset of B cells (B1a) cell and can regulate the T cell…”
Get full text

Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy by Gameiro, Steven F., Ghasemi, Farhad, Barrett, John W., Koropatnick, James, Nichols, Anthony C., Mymryk, Joe S., Maleki Vareki, Saman

“…Cancers progress when the immune system fails to identify and eliminate malignant cells. Recognition of this, combined with advances in tumor immunology, has…”
Get full text

Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines by Maleki Vareki, Saman, Salim, Kowthar Y, Danter, Wayne R, Koropatnick, James

“…Emerging drug-resistance and drug-associated toxicities are two major factors limiting successful cancer therapy. Combinations of chemotherapeutic drugs have…”
Get full text

Reduced CD5 on CD8 + T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function by Alotaibi, Faizah, Vincent, Mark, Min, Wei-Ping, Koropatnick, James

“…CD5, a member of the scavenger receptor cysteine-rich superfamily, is a marker for T cells and a subset of B cells (B1a). CD5 associates with T-cell and B-cell…”
Get full text

Silencing IDO in dendritic cells: A novel approach to enhance cancer immunotherapy in a murine breast cancer model by Zheng, Xiufen, Koropatnick, James, Chen, Di, Velenosi, Thomas, Ling, Hong, Zhang, Xusheng, Jiang, Nan, Navarro, Benjamin, Ichim, Thomas E., Urquhart, Bradley, Min, Weiping

“…Cancer immunotherapeutic agents (vaccines) in the form of antigen‐loaded dendritic cells (DCs) reached an important milestone with the recent approval of…”
Get full text

miR-149-3p reverses CD8 + T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells by Zhang, Meng, Gao, Dian, Shi, Yanmei, Wang, Yifan, Joshi, Rakesh, Yu, Qiongfang, Liu, Daheng, Alotaibi, Faizah, Zhang, Yujuan, Wang, Hongmei, Li, Qing, Zhang, Zhu-Xu, Koropatnick, James, Min, Weiping

“…Blockade of inhibitory receptors (IRs) is one of the most effective immunotherapeutic approaches to treat cancer. Dysfunction of miRNAs is a major cause of…”
Get full text

TdIF1-LSD1 Axis Regulates Epithelial-Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer by Liu, Qi, Xiong, Juan, Xu, Derong, Hao, Nan, Zhang, Yujuan, Sang, Yi, Wang, Zhigang, Zheng, Xiufen, Min, Jeffrey, Diao, Hong, Raphael, Jacques, Maleki Vareki, Saman, Koropatnick, James, Min, Weiping

“…We have previously found that TdT-interacting factor 1 (TdIF1) is a potential oncogene expressed in non-small cell lung cancer (NSCLC) and is associated with…”
Get full text

Voluntary running exercise protects against sepsis-induced early inflammatory and pro-coagulant responses in aged mice by Tyml, Karel, Swarbreck, Scott, Pape, Cynthia, Secor, Dan, Koropatnick, James, Feng, Qingping, Veldhuizen, Ruud A W, Gill, Sean E

“…Despite many animal studies and clinical trials, mortality in sepsis remains high. This may be due to the fact that most experimental studies of sepsis employ…”
Get full text

The Hyaluronan Receptors CD44 and Rhamm (CD168) Form Complexes with ERK1,2 That Sustain High Basal Motility in Breast Cancer Cells by Hamilton, Sara R., Fard, Shireen F., Paiwand, Frouz F., Tolg, Cornelia, Veiseh, Mandana, Wang, Chao, McCarthy, James B., Bissell, Mina J., Koropatnick, James, Turley, Eva A.

“…CD44 is an integral hyaluronan receptor that can promote or inhibit motogenic signaling in tumor cells. Rhamm is a nonintegral cell surface hyaluronan receptor…”
Get full text

IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells by Maleki Vareki, Saman, Chen, Di, Di Cresce, Christine, Ferguson, Peter J, Figueredo, Rene, Pampillo, Macarena, Rytelewski, Mateusz, Vincent, Mark, Min, Weiping, Zheng, Xiufen, Koropatnick, James

“…Indoleamine 2,3-dioxygenase-1 (IDO) is an immune regulatory enzyme expressed by most human tumors. IDO levels in tumor cells correlate with increased…”
Get full text

Detection of circulating tumor cells in advanced head and neck cancer using the cellsearch system by Nichols, Anthony C., Lowes, Lori E., Szeto, Christopher C. T., Basmaji, John, Dhaliwal, Sandeep, Chapeskie, Corina, Todorovic, Biljana, Read, Nancy, Venkatesan, Varugar, Hammond, Alex, Palma, David A., Winquist, Eric, Ernst, Scott, Fung, Kevin, Franklin, Jason H., Yoo, John, Koropatnick, James, Mymryk, Joe S., Barrett, John W., Allan, Alison L.

“…Background Early detection of circulating tumor cells (CTCs) offers the possibility of improved outcome for patients with head and neck squamous cell cancer…”
Get full text

498 Downregulation of CD5 in CD8+ T tumour-infiltrating lymphocytes associates with increased level of activation and exhaustion by Alotaibi, Faizah, Vincent, Mark, Min, Weiping, Koropatnick, James

“…BackgroundCD5, a member of the scavenger receptor cysteine-rich superfamily, is a marker for T cells and a subset of B cells (B1a). CD5 associates with T-cell…”
Get full text

Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients by CROMBET, Tania, OSORIO, Marta, FERNANDEZ, Eduardo, ALVAREZ, Daniel, TORRES, Olga, RAMOS, Mayra, LEONARD, Idrissa, PEREZ, Rolando, LAGE, Agustin, CRUZ, Teresa, ROCA, Carlos, DEL CASTILLO, Ramon, MON, Rosa, IZNAGA-ESCOBAR, Normando, FIGUEREDO, René, KOROPATNICK, James, RENGINFO, Enrique

“…To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy…”
Get full text

587 Inducing mismatch repair deficiency in combination with anti-CTLA4 therapy is highly effective against non-immunogenic neuroblastoma tumors by El-Hajjar, Mikal, Gerhardt, Lara, Krishnamoorthy, Mithunah, Figueredo, Rene, Zheng, Xiufen, Koropatnick, James, Maleki, Saman

“…BackgroundDespite rigorous multimodal therapy, recurrence is common among high-risk neuroblastoma patients. Neuroblastoma is a poorly immunogenic tumor with…”
Get full text

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2 by Rytelewski, Mateusz, Maleki Vareki, Saman, Mangala, Lingegowda S, Romanow, Larissa, Jiang, Dahai, Pradeep, Sunila, Rodriguez-Aguayo, Christian, Lopez-Berestein, Gabriel, Figueredo, Rene, Ferguson, Peter J, Vincent, Mark, Sood, Anil K, Koropatnick, James D

“…Human tumor heterogeneity promotes therapeutic failure by increasing the likelihood of resistant cell subpopulations. The PARP-1 inhibitor olaparib is approved…”
Get full text

Exosomes as a tumor immune escape mechanism: possible therapeutic implications by Ichim, Thomas E, Zhong, Zhaohui, Kaushal, Shalesh, Zheng, Xiufen, Ren, Xiubao, Hao, Xishan, Joyce, James A, Hanley, Harold H, Riordan, Neil H, Koropatnick, James, Bogin, Vladimir, Minev, Boris R, Min, Wei-Ping, Tullis, Richard H

“…Advances in cancer therapy have been substantial in terms of molecular understanding of disease mechanisms, however these advances have not translated into…”
Get full text

TdIF1: a putative oncogene in NSCLC tumor progression by Zhang, Yujuan, Wang, Zhigang, Huang, Yanqing, Ying, Muying, Wang, Yifan, Xiong, Juan, Liu, Qi, Cao, Fan, Joshi, Rakesh, Liu, Yanling, Xu, Derong, Zhang, Meng, Yuan, Keng, Zhou, Nanjin, Koropatnick, James, Min, Weiping

“…TdT-interacting factor 1 (TdIF1) is a ubiquitously expressed DNA- and protein-binding protein that directly binds to terminal deoxynucleotidyl transferase…”
Get full text

Reinstalling Antitumor Immunity by Inhibiting Tumor-Derived Immunosuppressive Molecule IDO through RNA Interference by Zheng, Xiufen, Koropatnick, James, Li, Mu, Zhang, Xusheng, Ling, Fengjun, Ren, Xiubao, Hao, Xishan, Sun, Hongtao, Vladau, Costin, Franek, Jacob A, Feng, Biao, Urquhart, Bradley L, Zhong, Robert, Freeman, David J, Garcia, Bertha, Min, Wei-Ping

“…Tumor-derived immune suppression is a major impediment to successful immune/gene cancer therapy. In the present study, we describe a novel strategy to disrupt…”
Get full text

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? by Ichim, Thomas E, Minev, Boris, Braciak, Todd, Luna, Brandon, Hunninghake, Ron, Mikirova, Nina A, Jackson, James A, Gonzalez, Michael J, Miranda-Massari, Jorge R, Alexandrescu, Doru T, Dasanu, Constantin A, Bogin, Vladimir, Ancans, Janis, Stevens, R Brian, Markosian, Boris, Koropatnick, James, Chen, Chien-Shing, Riordan, Neil H

“…The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day…”
Get full text

In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract by Ferguson, P.J, Kurowska, E.M, Freeman, D.J, Chambers, A.F, Koropatnick, J

“…Edible fruits and berries may serve as sources for novel anticancer agents, given that extracts of these foods have demonstrated cytotoxic activity against…”
Get full text